Here, we evaluated the immune properties of the HLA-A2 restricted CD8⁺ T?cell epitopes containing mutations from B.1.1.7, and furthermore performed a comprehensive analysis of the SARS-CoV-2 specific CD8⁺ T?cell responses from COVID-19 convalescent patients and SARS-CoV-2 vaccinees recognizing the ancestral Wuhan strain compared to B.1.1.7. First, most of the predicted CD8⁺ T?cell epitopes showed proper binding with HLA-A2, whereas epitopes from B.1.1.7 had lower binding capability than those from the ancestral strain. In addition, these peptides could effectively induce the activation and cytotoxicity of CD8⁺ T?cells. Our results further showed that at least two site mutations in B.1.1.7 resulted in a decrease in CD8⁺ T?cell activation and a possible immune evasion, namely A1708D mutation in ORF1ab_1707-1716 and I2230T mutation in ORF1ab_2230-2238. Our current analysis provides information that contributes to the understanding of SARS-CoV-2-specific CD8⁺ T?cell responses elicited by infection of mutated strains or vaccination.